BeOne Raises 2026 Revenue Outlook to $7 Billion
The biotech company lifted its full-year revenue projection after third-quarter sales rose 34% to $1.4 billion.
Updated on Nov. 7, 2026 in Cancer
BeOne Medicines raised its 2026 revenue projection to $6.9 billion to $7 billion after reporting third-quarter sales of $1.4 billion, up 34% from the year-earlier period. U.S. sales of BRUKINSA exceeded $1 billion during the quarter.
Why it matters
The revenue increase reflects strong demand for the company's cancer treatments in the United States, where BRUKINSA sales topped $1 billion in a single quarter. Management also flagged biosimilar competition for XGEVA and possible value-based purchasing pressure on key products beyond 2026.
BeOne reported third-quarter sales of $1.4 billion, up 34% from a year earlier, with U.S. BRUKINSA sales exceeding $1 billion in the quarter. The company's 2026 revenue projection now stands at $6.9 billion to $7 billion, though the source does not state the prior guidance range for comparison.
The players
BeOne Medicines
BeOne Medicines is a biopharmaceutical company that markets the cancer drug BRUKINSA and is developing tacabrutideg for chronic lymphocytic leukemia.
The details
BeOne plans to submit an accelerated-approval application for tacabrutideg in relapsed or refractory chronic lymphocytic leukemia around mid-2027, a timetable that follows an FDA request for additional follow-up. The FDA also granted BRUKINSA priority review for treatment-naive mantle cell lymphoma.
Timeline
2026: BeOne raised its full-year revenue projection.
Third quarter 2026: Sales reached $1.4 billion, up 34%.
Mid-2027: Planned submission of the tacabrutideg accelerated-approval application for CLL.
Health Landscape
Management's warning that higher manufacturer liability under Medicare Part D could be a flat to modest headwind next year ties this quarter's results to ongoing federal drug-cost rules. Biosimilar competition for XGEVA and possible value-based purchasing for XGEVA and Kyprolis point to pricing pressure that will shape the company's cancer franchise after 2026.
Patients with relapsed or refractory CLL may eventually have access to tacabrutideg if the planned accelerated-approval application is granted. The pending FDA priority review for BRUKINSA in treatment-naive mantle cell lymphoma could expand the drug's use for newly diagnosed patients.
The takeaway
Strong U.S. demand for BRUKINSA is driving BeOne's growth, but the company's outlook depends on managing biosimilar competition and evolving federal pricing rules. Investors and patients alike should watch how these pressures play out after 2026.
What happens next
BeOne plans to submit an accelerated-approval application for tacabrutideg in CLL around mid-2027.
Further reading
Explore more on Cancer developments and treatment advances.
Source note: This article includes information reported by TokenPost.
